Cost Utility Analysis in Recurrent Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00813254|
Recruitment Status : Withdrawn
First Posted : December 23, 2008
Last Update Posted : April 19, 2012
The goal of this research study is to learn about the quality of life and sexual functioning of women with platinum-resistant ovarian cancer as they receive other treatments for the disease.
Researchers will study the costs for chemotherapy treatments, other medical expenses, and treatment-related expenses that are not medical. Researchers will also review any symptoms these patients may experience related to the cancer or treatment.
In addition, researchers want to learn if and how these patients' caregivers feel the status of these patients' health may have affected the caregivers' productivity at work and at home.
|Condition or disease||Intervention/treatment|
|Ovarian Cancer||Behavioral: Questionnaire|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
Other Name: Survey
- Mean Score for the FACT-O instrument [ Time Frame: First 2 days of chemotherapy cycles ]Participants will complete questionnaires 1 - 5 at baseline and Day 1 of each of their chemotherapy cycles.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00813254
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Michael M Frumovitz, MD||M.D. Anderson Cancer Center|